Envoy Medical shares jump 17.83% after-hours as Acclaim trial completes six-month milestone with no adverse events, reinforcing FDA submission and commercialization plans.

Envoy Medical (NASDAQ: COCH) surged 17.83% in after-hours trading following the announcement that all 10 patients in the first stage of its Acclaim cochlear implant trial completed six-month follow-up visits with no serious adverse events. The milestone reinforces the device’s safety profile and advances the company’s timeline for FDA submission and commercialization. The update, coupled with trial expansion and recent patent issuances, signals clinical progress and growing confidence in the device’s market potential. The Acclaim implant holds FDA Breakthrough Device Designation, and the positive safety data from the initial cohort align with Envoy’s strategic goals, bolstering investor optimism about its long-term prospects in the hearing health sector.